AKTS Strangle Strategy
AKTS (Aktis Oncology, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020.
AKTS (Aktis Oncology, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.28B, a beta of 0.45 versus the broader market, a 52-week range of 14.72-34.19, average daily share volume of 334K, a public-listing history dating back to 2026, approximately 79 full-time employees. These structural characteristics shape how AKTS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.45 indicates AKTS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on AKTS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
AKTS snapshot
As of August 14, 2026, spot at $24.77, ATM IV 110.30%, IV rank 63.01%, expected move 31.62%. The strangle on AKTS below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on AKTS specifically: AKTS IV at 110.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 31.62% (roughly $7.83 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AKTS expiries trade a higher absolute premium for lower per-day decay. Position sizing on AKTS should anchor to the underlying notional of $24.77 per share and to the trader's directional view on AKTS stock.
AKTS strangle setup
The AKTS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AKTS at $24.77 on that close, the first option leg uses a $26.01 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AKTS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AKTS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $26.01 | N/A |
| Buy 1 | Put | $23.53 | N/A |
AKTS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
AKTS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on AKTS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on AKTS
Strangles on AKTS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AKTS chain.
AKTS thesis for this strangle
The market-implied 1-standard-deviation range for AKTS extends from approximately $16.94 on the downside to $32.60 on the upside. A AKTS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current AKTS IV rank near 63.01% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on AKTS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, AKTS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AKTS-specific events.
AKTS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AKTS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AKTS alongside the broader basket even when AKTS-specific fundamentals are unchanged. Always rebuild the position from current AKTS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on AKTS?
- A strangle on AKTS is the strangle strategy applied to AKTS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With AKTS stock at $24.77 on the most recent close, the strikes shown on this page are snapped to the nearest listed AKTS chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are AKTS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the AKTS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 110.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AKTS strangle?
- The breakeven for the AKTS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The AKTS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 31.62%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on AKTS?
- Strangles on AKTS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AKTS chain.
- How does current AKTS implied volatility affect this strangle?
- AKTS ATM IV is at 110.30% with IV rank near 63.01%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.